Table 1. Current clinical trials targeting myeloid checkpoints.
| Target | Agent | Interventions | Company | Study phase/status | Clinical trial ID | Conditions or diseases |
| LILRB, leukocyte immunoglobulin-like receptor B; Siglec, sialic acid-binding immunoglobulin-type lectin; NRP1, neuropilin-1; Cleve1, commonlymphatic endothelial and vascular endothelial receptor-1; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia. | ||||||
| CD47/ SIRPα |
HX009 | Anti-CD47/PD-1 bifunctional antibody | Waterstone Hanxbio Pty Ltd. | Phase 2/Recruiting | NCT04886271 | Advanced solid tumor |
| IBI188, Rituximab | Anti-CD47 monoclonal antibody | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/Active | NCT03717103 | Advanced malignancies | |
| IBI188 | Anti-CD47 monoclonal antibody | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/Completed | NCT03763149 | Advanced malignancies | |
| Magrolimab | Anti-CD47 monoclonal antibody | University of California, San Francisco & Gilead Sciences | Phase 1/Not yet recruiting | NCT05169944 | Children and adults with recurrent or progressive malignant brain tumors | |
| STI-6643 | − | Sorrento Therapeutics, Inc. | Phase 1/Recruiting | NCT04900519 | Advanced solid tumors | |
| CC-90002 Rituximab |
− | Celgene | Phase 1/Completed | NCT02367196 | Advanced solid and hematologic cancers | |
| TTI-621 | Soluble recombinant fusion protein | Trillium Therapeutics Inc. | Phase 1/Recruiting | NCT02663518 | Hematologic malignancies and selected solid tumors | |
| Hu5F9-G4 | Anti-CD47 monoclonal antibody | Gilead Sciences | Phase 1/Phase 1 | NCT02678338 | Hematological malignancies | |
| Hu5F9-G4 | − | Gilead Sciences | Phase 1/Phase 1 | NCT02216409 | Solid tumors | |
| PF-07257876 |
CD47-PD-L1 bispecific antibody | Pfizer | Phase 1/Recruiting | NCT04881045 | Selected advanced tumors | |
| Magrolimab | Monotherapy or in combination with Azacitidine | Gilead Sciences | Phase 1/Recruiting | NCT03248479 | Hematological malignancies | |
| SRF231 | − | Surface Oncology | Phase 1/Completed | NCT03512340 | Advanced solid and hematologic cancers | |
| AK117 | Anti-CD47 | Akeso | Phase 1/Recruiting | NCT04728334 | Malignant neoplasms | |
| TQB2928 | New molecular entity | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/Not yet recruiting | NCT04854681 | Advanced solid tumors and hematological malignancies | |
| IMC-002 | Blocking the interaction between CD47 and SIRPα | ImmuneOncia Therapeutics Inc. | Phase 1/Recruiting | NCT04306224 | Metastatic or locally advanced solid tumors and relapsed or refractory lymphomas | |
| IBI322 | Recombinant anti-human CD47/PD-L1 bispecific antibody | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/Recruiting | NCT04328831 | Advanced malignancies | |
| IMM2902 | HER2/SIRPα bispecific mAb-trap antibody-receptor fusion protein | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. | Phase 1/Not yet recruiting | NCT05076591 | HER2-expressing advanced solid tumors | |
| AO-176 | Humanized monoclonal antibody (mAb) targeting CD47 | Arch Oncology | Phase 1/2/Recruiting | NCT03834948 | Solid tumor malignancies | |
| IBC0966 | − | SUNHO (China) BioPharmaceutical CO., Ltd. | Phase 1/2/Not yet recruiting | NCT04980690 | Advanced malignant tumors | |
| IBI322 | Recombinant anti-human CD47/PD-L1 bispecific antibody | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/Not yet recruiting | NCT04338659 | Advanced malignancies | |
| IBI322 | IBI322 monotherapy or combination therapy | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/Not yet recruiting | NCT04912466 | Advanced malignant tumors | |
| IBI322+HMA | IBI322 monotherapy or combination therapy with HMA | Innovent Biologics (Suzhou) Co. Ltd. | Phase Ia/Ib/Not yet recruiting | NCT05148442 | Myeloid tumors | |
| TTI-621 | Soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1) | Trillium Therapeutics Inc. | Phase 1/Terminated | NCT02890368 | Relapsed and refractory solid tumors and mycosis fungoides | |
| TTI-621+TTI-622 | TTI-621 and TTI-622 in combination with daratumumab hyaluronidase-fihj | Memorial Sloan Kettering Cancer Center | Phase 1/Recruiting | NCT05139225 | Multiple myeloma | |
| AK117 | Anti-CD47 antibody | Akeso | Phase 1/2/Recruiting | NCT04980885 | Acute myeloid leukemia | |
| AK117 | Anti-CD47 antibody | Akeso | Phase 1/2/Recruiting | NCT04900350 | Myelodysplastic syndrome | |
| ALX148 (Evorpacept) | − | ALX Oncology Inc. | Phase 1/Active, not recruiting | NCT03013218 | Advanced solid tumors and lymphoma | |
| ALX148 | Combination with trastuzumab, ramucirumab, and paclitaxel | ALX Oncology Inc. | Phase 2/3/Not yet recruiting | NCT05002127 | HER2+ gastric cancer gastric cancer | |
| ALX148 | Evaluating the combination of ALX148, cetuximab, and pembrolizumab | Criterium, Inc. | Phase 2/Not yet recruiting | NCT05167409 | Microsatellite stable metastatic colorectal cancer | |
| AO-176 | AO-176 as monotherapy and in combination with bortezomib/dexamethasone | Arch Oncology | Phase 1/2/Recruiting | NCT04445701 | Relapsed/refractory multiple myeloma | |
| CC-90002 | Monoclonal Ab to CD47 | Celgene | Terminated | NCT02641002 | AML and high-risk MDS | |
| CPO107/ JMT601 | CD20−CD47 bispecific fusion protein | Conjupro Biotherapeutics, Inc. | Phase 1/2/Not yet recruiting | NCT04853329 | CD20 positive non-Hodgkin lymphoma | |
| TG-1801 | Bispecific CD47 and CD19 antibody | TG Therapeutics, Inc. | Phase 1/Recruiting | NCT04806035 | B-cell lymphoma or chronic lymphocytic leukemia | |
| Lemzoparlimab (TJC4) | CD47-SIRPα antibody | AbbVie | Phase 1 | NCT04912063 | AML; MDS | |
| SL-172154 | Fusion protein consisting of human SIRPα and CD40L (SIRPα-Fc-CD40L) linked via a human Fc | Shattuck Labs, Inc. | Phase 1/Recruiting | NCT04502888 | Squamous cell carcinoma of the head and neck or skin | |
| TJ1133 | Anti-CD47 antibody | The First Affiliated Hospital of Bengbu Medical College | Phase 1/2/Recruiting | NCT05148533 | Advanced solid tumors | |
| SLAMF7 | SLAMF7 BATs | Combining anti-CD3 x anti-SLAMF7 bispecific antibody | University of Virginia | Phase 1/Not yet recruiting | NCT04864522 | Relapsed/Refractory multiple myeloma |
| Anti-SLAMF7 | Anti-SLAMF7 monoclonal antibody | University of Arkansas | Phase 2/Withdrawn (No study population. No subjects enrolled.) | NCT03168100 | Multiple myeloma | |
| Anti-SLAMF7 | Anti-SLAMF7 monoclonal antibody | University of Arkansas | Phase 2/Withdrawn (No study population. No subjects enrolled.) | NCT03000634 | Multiple myeloma during maintenance therapy | |
| Elotuzumab | mAb directed against the extracellular domain of SLAMF7 | Tulane University School of Medicine | Phase 2/Not yet recruiting | NCT05170789 | Relapsed refractory multiple myeloma | |
| Elotuzumab | Elotuzumab in combination with carfilzomib, lenalidomide and dexamethasone (E-KRd) | Wuerzburg University Hospital | Phase 3/Active, not recruiting | NCT03948035 | Newly diagnosed multiple myeloma | |
| Elotuzumab | − | University of Arkansas | Phase 2/Withdrawal of study support | NCT03003728 | High-risk myeloma post- autologous stem cell transplant | |
| Elotuzumab | Lenalidomide and dexamethasone with or without elotuzumab | Bristol-Myers Squibb | Phase 3/Terminated (Insufficient enrollment) | NCT01891643 | Newly diagnosed, previously untreated multiple myeloma | |
| Biological: Elotuzumab | Expanded access to elotuzumab (empliciti) for multiple myeloma | Bristol-Myers Squibb | No longer available | NCT03126617 | Multiple myeloma | |
| Biological: BCMA-CS1 cCAR T cells | − | iCell Gene Therapeutics | Early phase 1/Unknown | NCT04156269 | Multiple myeloma | |
| Biological: Elotuzumab | Anti-SLAMF7 monoclonal antibody | M.D. Anderson Cancer Center | Phase 2/Recruiting | NCT04517851 | JAK2-mutated myelofibrosis | |
| LILRB1 | BND-22 | − | Biond Biologics | Phase 1/2/Recruiting | NCT04717375 | Advanced solid tumors |
| NGM707 | LILRB1/LILRB2 bispecific antibody | NGM Biopharmaceuticals, Inc. | Phase 1/2/Recruiting | NCT04913337 | Advanced or metastatic solid tumor malignancies | |
| LILRB2 | JTX 8064 | As monotherapy or in combination with PD-1 inhibitor | Jounce Therapeutics, Inc. | Phase 1/Recruiting | NCT04669899 | Advanced refractory solid tumors |
| IO-108 | As monotherapy or in combination with pembrolizumab | Immune-Onc Therapeutics Inc. | Phase 1/Recruiting | NCT05054348 | Solid tumors | |
| MK-4830 | − | Merck Sharp & Dohme Corp | Phase 1/Recruiting | NCT03564691 | Advanced solid tumors | |
| LILRB4 | IO-202 | Monotherapy or plus azacitidine | Immune-Onc Therapeutics Inc. | Phase 1/Recruiting | NCT04372433 | AML and CMML |
| IO-202 | Monotherapy or in combination with pembrolizumab | Immune-Onc Therapeutics Inc | Phase 1/Not yet recruiting | NCT05309187 | Solid cancer | |
| MK-0482 | In combination with pembrolizumab | Merck Sharp & Dohme LLC | Phase 2 | NCT04165096 | Non-small-cell lung carcinoma, acute leukemia, myeloid, neoplasms | |
| TREM2 | PY314 | PY314 or in combination with pembrolizumab | Pionyr Immunotherapeutics Inc. | Phase 1/Recruiting | NCT04691375 | Advanced solid tumors |
| Siglec15 | NC318 | NC318 or in combination with pembrolizumab | Yale University New Haven, Connecticut, United States | Phase 2/Recruiting | NCT04699123 | Advanced non-small cell lung cancer |
| NRP1 | ASP1948 | ASP1948 or in combination with nivolumab or pembrolizumab | Astellas Pharma Global Development, Inc. | Phase 1b | NCT03565445 | Advanced solid tumors |
| Clever1 | Bexmarilimab | Dose-escalation, six dose levels | The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States | Phase I/II | NCT03733990 | Advanced solid tumors |